低中危口咽癌:TORS联合颈清扫与非手术治疗的吞咽困难比较
该研究为单中心前瞻性注册数据的二次分析,纳入257例低中危HPV相关口咽鳞癌患者,比较原发TORS(75例)与放疗(182例)的吞咽结局。TORS后急性中重度吞咽困难发生率为22.7%,3-6个月降至6.7%,放疗组为15.9%;两组亚急性吞咽结局相似。
要点
- TORS后急性中重度吞咽困难(DIGEST≥2)发生率为22.7%,与肿瘤体积相关。
- 3-6个月时TORS组DIGEST≥2比例为6.7%,放疗组为15.9%。
- 两组在3-6个月时吞咽结局趋于一致,亚急性结局相似。
核心结论
- 在低中危口咽鳞癌患者中,无论原发治疗方式如何,亚急性吞咽结局相似。
研究设计与样本
- 单中心前瞻性注册数据的二次分析,纳入2015年3月1日至2018年2月28日入组的257例患者。
- 患者按原发治疗分层:75例接受TORS,182例接受放疗。
主要发现
- TORS后吞咽困难严重程度显著恶化(r=-0.63;95%CI,-0.78至-0.44)。
- 17例(22.7%;95%CI,13.8%-33.8%)患者TORS后出现中重度急性吞咽困难,与原发性肿瘤体积相关(OR=1.43;95%CI,1.11-1.84)。
- 3-6个月时DIGEST≥2者:TORS组5例(6.7%;95%CI,2.2%-14.9%),放疗组29例(15.9%;95%CI,10.9%-22.1%)。
- 放疗开始时,TORS后组MDASI吞咽症状严重程度评分较诱导后(平均变化2.6[1.1])和治疗初治(平均变化1.7[0.3])患者更差,但放疗结束时逆转,3-6个月时各组趋同。
关键数值与推荐
- 中重度吞咽困难定义为DIGEST分级≥2。
- 吞咽评估采用改良钡餐吞咽研究(MBS)按DIGEST分级,及MD Anderson症状量表头颈模块(MDASI-HN)问卷。
临床怎么用
- 对于低中危口咽癌患者,TORS和放疗均可作为原发治疗选择,亚急性吞咽结局相似。
- TORS后应关注急性吞咽困难,尤其肿瘤体积较大的患者。
局限性
- 本研究为单中心回顾性二次分析,样本量有限,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A major goal of primary transoral robotic surgery (TORS) for oropharyngeal cancer is to optimize swallowing outcomes by personalized treatment based on pathologic staging. However, swallowing outcomes after TORS are uncertain, as are the outcomes compared with nonsurgical options. OBJECTIVES: To estimate rates of acute dysphagia and recovery after TORS and to compare swallowing outcomes by primary treatment modality (TORS or radiotherapy). DESIGN, SETTING, AND PARTICIPANTS: This case series study was a secondary analysis of prospective registry data from 257 patients enrolled from March 1, 2015, to February 28, 2018, at a single academic institution who, according to the AJCC Staging Manual, 7th edition TNM classification, had low- to intermediate-risk human papillomavirus-related oropharyngeal squamous cell carcinoma possibly resectable by TORS. EXPOSURE: Patients were stratified by primary treatment (75 underwent TORS and 182 received radiotherapy). MAIN OUTCOMES AND MEASURES: Modified barium swallow (MBS) studies graded per Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) and the MD Anderson Symptom Inventory-Head and Neck Module (MDASI-HN) questionnaires were administered at standard intervals. Prevalence and severity of dysphagia were estimated per DIGEST before and after TORS and 3 to 6 months after treatment. Moderate-severe dysphagia (DIGEST grade ≥2) was assessed using logistic regression and compared by primary treatment group. The MDASI swallowing symptom severity item scores during and after radiotherapy were compared using generalized estimating equations by treatment status at the start of radiotherapy, after induction, and after TORS. RESULTS: A total of 257 patients (mean [SD] age, 59.54 [9.07] years; 222 [86.4%] male) were included in the study. Dysphagia severity (per DIGEST) was significantly worse after TORS (r = -0.63; 95% CI, -0.78 to -0.44): 17 patients (22.7%; 95% CI, 13.8%-33.8%) had moderate-severe (DIGEST grade ≥2) acute post-TORS dysphagia significantly associated with primary tumor volume (odds ratio, 1.43; 95% CI, 1.11-1.84). DIGEST improved by 3 to 6 months but remained worse than that at baseline; at 3 to 6 months, the number of patients with DIGEST grade 2 or higher dysphagia was 5 (6.7%; 95% CI, 2.2%-14.9%) after primary TORS and 29 (15.9%; 95% CI, 10.9%-22.1%) after radiotherapy. At the start of radiotherapy, MDASI swallowing symptom severity item scores were significantly worse in the post-TORS group compared with postinduction (mean [SD] change, 2.6 [1.1]) and treatment-naive (mean [SD] change, 1.7 [0.3]) patients. This result inverted at radiotherapy end, and all groups converged at 3 to 6 months. CONCLUSIONS AND RELEVANCE: Subacute swallowing outcomes were similar regardless of primary treatment modality among patients with low- to intermediate-risk oropharyngeal squamous cell carcinoma.
引用
- Hutcheson KA, Warneke CL, Yao CMKL, et al. Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 31556933. doi:10.1001/jamaoto.2019.2725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。